Core Insights - IceCure Medical has received approval from Swissmedic for the ProSense® system, expanding its global market access following recent FDA authorization for low-risk breast cancer treatment [1] Company Developments - The ProSense® system and cryoprobes are now officially registered for the treatment of malignant or benign tissue in various organs, including the breast, lung, liver, kidney, and musculoskeletal system [1] - This approval supports IceCure's commercial momentum and enhances its position in the minimally-invasive cryoablation technology market [1]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Legal Action and Investor Rights - Shareholders who purchased Tandem Diabetes Care securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to the misleading information [2]. Group 2: Company Incident and Stock Impact - On August 7, 2025, Tandem Diabetes Care announced a voluntary medical device correction for select t:slim X2 insulin pumps due to a potential speaker-related issue that could lead to insulin delivery discontinuation [3]. - Following this announcement, Tandem Diabetes' stock experienced a significant decline of 19.9% on the same day [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked highly for the number of settlements [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Summary of Zimmer Biomet Conference Call Company Overview - **Company**: Zimmer Biomet - **Industry**: Orthopedic Medical Technology Key Points Market Conditions - The orthopedic markets are healthy, with a projected market size of **$4 to $4.25 billion** [2][3] - The company expects both pricing and volume to remain stable over the next two years [3] Innovation - Zimmer Biomet is transitioning from competition-centric innovation to customer-centric innovation [4] - The company is launching several new products, including: - **Anti-infective platforms** and **smart implants** [4][5] - **Solder robotics** and **autonomous robotics** [5] - The company has filled all gaps in its product portfolio, particularly in hips and knees [21] Execution Challenges - The company acknowledges inconsistent execution, with some quarters performing better than others [5][6] - Specific operational challenges were noted, including an ERP issue and unexpected order delays from Latin America and emerging markets [10][11] - The company plans to improve forecasting practices and eliminate volatile distributors [11][12] Financial Performance - In Q3, Zimmer Biomet achieved **5.6% organic growth** in the U.S., the best performance in two years [8] - The company missed revenue consensus by **$9 million** in Q3 but over-delivered on EPS [12] - The company maintains a strong balance sheet with **$1.7 billion in adjusted EBITDA** and over **$1 billion in free cash flow** [40] Guidance and Future Outlook - The company will adopt a more measured approach to quarterly guidance moving forward [12][13] - The focus will be on maintaining consistent performance and addressing operational challenges [6][7] - The company expects to see continued strong demand and pricing stability in key markets [19] Competitive Landscape - The spinoff of a major competitor, Johnson & Johnson's orthopedic business, may create market disruption that Zimmer Biomet can leverage [42][43] Product Launches and Market Strategy - Upcoming product launches include: - An **iodine-coated hip implant** in Japan, expected to command a **40%-50% premium** on pricing [29] - Full launches of **smart implants** and **solder robotics** in 2026 [23] - The company is focused on integrating recent acquisitions, including Paragon 28 and Monogram, to enhance its market position [35][40] Margin and Cost Management - Gross margins are expected to improve modestly in 2025, driven by product mix and efficiency gains [31] - The company is addressing tariff headwinds and foreign exchange pressures while focusing on revenue growth to support margin expansion [32] Capital Allocation - Zimmer Biomet is prioritizing integration of recent acquisitions and is open to opportunistic buybacks [37][40] Conclusion Zimmer Biomet is positioned to capitalize on a healthy orthopedic market through innovation and strategic execution, despite facing some operational challenges. The company is focused on maintaining consistent performance and leveraging market disruptions from competitors.

Financial Performance - Medtronic reported a strong Q2 FY26 with 6.6% reported revenue growth and 5.5% organic revenue growth[17, 22] - Adjusted diluted EPS grew by 8% year-over-year[13, 20] - The company is raising FY26 revenue guidance by 50 bps to 5.5% and EPS guidance to $5.62-$5.66[13] - Adjusted gross margin expanded by 70 bps due to continued COGS efficiency program execution[15, 22] - The company is expecting ~$185 million tariff impact to COGS[54] Segment Performance - Cardiovascular segment showed strong performance with 9.3% organic growth[15, 21] - Cardiac Ablation Solutions (CAS) grew by 71% year-over-year, with 128% US growth[15, 39, 40] - Neuroscience segment grew by 3.9% organically[21] - Diabetes segment grew by 7.1% organically[21] - Medical Surgical segment grew by 1.3% organically[21] Strategic Initiatives - Medtronic is progressing toward Diabetes business separation by the end of CY26, with a preferred path of IPO and split-off[15, 47] - The company is increasing investments in enterprise growth drivers, organic R&D, and sales/marketing[15] - Medtronic is expecting to add incremental $1 billion revenue from Cardiac Ablation Solutions off FY25 base[33] Product and Market Highlights - The company received US FDA approval for Altaviva for treating urge urinary incontinence[15, 28] - Symplicity Spyral received PMDA approval in Japan and US CMS finalized National Coverage Determination[28, 29] - The company is launching new products and driving commercial execution, expecting growth to accelerate in H2 and beyond[15]

Group 1 - Inspire Medical Systems, Inc. is a medical technology company focused on developing and commercializing innovative, minimally invasive solutions for patients with obstructive sleep apnea [3] - The company will present at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, at 11:30 a.m. Eastern Time [1][2] - Inspire's proprietary Inspire therapy is the first and only FDA, EU MDR, and PDMA-approved neurostimulation technology for treating moderate to severe obstructive sleep apnea [3]

Core Insights - Catheter Precision, Inc. has secured its first multi-year agreement in France for the VIVO™ system, marking a significant commitment to the French electrophysiology market [1][4] - The VIVO system will be installed at the Centre Hospitalier Régional Universitaire (CHRU) Nancy, enhancing the hospital's capabilities in complex arrhythmia ablation [1][2] - This follows a successful deployment at CHU Rennes, which was Catheter Precision's largest purchase order in Europe, indicating strong demand and positive early results [3][4] Company Overview - Catheter Precision is a US-based medical device company focused on developing advanced technologies for cardiac electrophysiology [6] - The company aims to improve treatment for cardiac arrhythmias through innovative solutions and collaboration with healthcare professionals [6] Product Details - The VIVO system is a non-invasive 3D imaging technology that helps physicians identify the origins of ventricular arrhythmias before procedures, thereby streamlining workflows and reducing procedure times [5] - VIVO has received marketing clearance from both the U.S. FDA and has the CE Mark, indicating its compliance with regulatory standards [5] Market Position - The installation of VIVO at prestigious hospitals like CHRU Nancy and CHU Rennes reflects the growing momentum and clinical value of the product in the French market [4] - The involvement of leading academic centers is crucial for the early adoption of VIVO among physicians, which is expected to drive long-term usage [4]

Core Insights - Medtronic raised its fiscal-year outlook due to higher profit and sales in its latest quarter [1] - The increase in performance was driven by robust demand across end markets and healthy procedure volumes [1] Financial Performance - The company reported higher profit and sales compared to previous periods [1] - The fiscal-year outlook has been positively adjusted in response to these results [1] Market Demand - There is strong demand across various end markets, contributing to the company's growth [1] - Healthy procedure volumes indicate a positive trend in operational activity [1]

Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. Global equities continue to rally in the third quarter, the period with double-digit YTD gains. Major US indices like Russell 1000®, Russell Midcap®, and Russell 2000® reached record highs in the period. In the quarter, the fund’s Investor Class fund ARTSX returned 8.69%, Advisor Class fund APDSX posted a return of 8.75%, and Institutional ...

Core Viewpoint - Apyx Medical Corporation has announced a public offering of 2,762,431 shares of its common stock at a price of $3.62 per share, with the offering expected to close on or about November 19, 2025 [1][2]. Group 1: Offering Details - The offering is underwritten by Lucid Capital Markets, which is acting as the sole book-running manager [2]. - The company has granted the underwriter a 45-day option to purchase an additional 414,365 shares at the public offering price [2]. - The net proceeds from the offering will be used for working capital and general corporate purposes [3]. Group 2: Regulatory and Documentation - The offering is made pursuant to a shelf registration statement filed with the SEC, which was declared effective on December 2, 2022 [3]. - A preliminary prospectus supplement and accompanying prospectus have been filed with the SEC and are available on their website [4]. Group 3: Company Overview - Apyx Medical Corporation specializes in surgical aesthetics, offering products like Renuvion and the AYON Body Contouring System, which provide innovative solutions in cosmetic surgery [6]. - The company’s technologies, including Helium Plasma Platform Technology, are supported by over 90 clinical documents, demonstrating their effectiveness [6]. - The AYON Body Contouring System is FDA-cleared and designed to integrate multiple surgical capabilities, enhancing the treatment options available to surgeons [6].

Group 1 - The company has decided to separate into two entities, RemainCo and NewCo, due to differing growth profiles and investment opportunities [2] - The separation was announced during the Q4 earnings call in February, indicating a strategic shift in capital allocation processes [2] - Since the announcement, the company has received more inbound interest in the assets than initially anticipated [3]